Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Why AdaptHealth Is On Investors’ Radar Today
AdaptHealth (AHCO) has drawn fresh attention after recent trading left the stock with a 1 day return of 2.7% and a year to date gain of 21.3%, inviting a closer look at its fundamentals.
See our latest analysis for AdaptHealth.
While the share price has pulled back, with a 7 day share price return of a 10.5% decline and a 30 day share price return of a 1.8% decline, the year to date share price return of 21.3% and 1 year total shareholder return of 40.1% suggest momentum has been building over a longer horizon.
If AdaptHealth has you looking closer at healthcare, it could be a good moment to widen your watchlist with 35 healthcare AI stocks
With AdaptHealth trading at $11.73 alongside an intrinsic discount of 63.3% and a 17.2% gap to analyst targets, you have to ask: is the stock still underappreciated, or is the market already pricing in future growth?
Most Popular Narrative: 23.5% Overvalued
At a last close of $11.73 against a narrative fair value of $9.50, the most followed view sees AdaptHealth as pricing in more than its modeled worth, and pins that on how earnings and margins could evolve.
Despite successfully divesting non-core segments and reducing net leverage, AdaptHealth’s need to maintain higher-than-planned infrastructure expenses and invest ahead of revenue for contract ramp-up creates a near-term gap between revenue growth and EBITDA realization. This means net margins and return on invested capital may not recover as quickly as expected, amplifying the risk of underperformance if contract ramp or segment execution falters.
Want to see what sits behind that caution on margins and returns? The narrative leans on specific paths for revenue, earnings, and future valuation multiples that are far from consensus.
Result: Fair Value of $9.50 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are also risks that could challenge this cautious view, including a smoother than expected capitated contract ramp and less severe reimbursement pressure than feared.
Find out about the key risks to this AdaptHealth narrative.
Another Angle On Valuation
The bearish narrative pegs fair value at $9.50, suggesting AdaptHealth is 23.5% overvalued at $11.73. However, our DCF model indicates a future cash flow value of $31.99 and a 63.3% discount to that estimate. When two models disagree this much, which one would you lean on?
